02:26:09 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2025-02-27 Bokslutskommuniké 2024
2024-10-24 Kvartalsrapport 2024-Q3
2024-07-12 Kvartalsrapport 2024-Q2
2024-05-21 Årsstämma 2024
2024-05-17 X-dag ordinarie utdelning ICO 0.00 SEK
2024-04-25 Kvartalsrapport 2024-Q1
2024-03-06 Extra Bolagsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-10-27 Extra Bolagsstämma 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-07-14 Kvartalsrapport 2023-Q2
2023-05-23 X-dag ordinarie utdelning ICO 0.00 SEK
2023-05-22 Årsstämma 2023
2023-04-28 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2022-10-28 Kvartalsrapport 2022-Q3
2022-07-15 Kvartalsrapport 2022-Q2
2022-05-19 X-dag ordinarie utdelning ICO 0.00 SEK
2022-05-17 Årsstämma 2022
2022-04-29 Kvartalsrapport 2022-Q1
2022-02-18 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-20 X-dag ordinarie utdelning ICO 0.00 SEK
2021-05-19 Årsstämma 2021
2021-04-29 Kvartalsrapport 2021-Q1
2021-02-17 Bokslutskommuniké 2020
2020-10-27 Kvartalsrapport 2020-Q3
2020-08-19 Kvartalsrapport 2020-Q2
2020-05-11 X-dag ordinarie utdelning ICO 0.00 SEK
2020-05-08 Kvartalsrapport 2020-Q1
2020-05-08 Årsstämma 2020
2020-03-11 Extra Bolagsstämma 2020
2020-02-14 Bokslutskommuniké 2019
2019-10-25 Kvartalsrapport 2019-Q3
2019-08-16 Kvartalsrapport 2019-Q2
2019-05-16 X-dag ordinarie utdelning ICO 0.00 SEK
2019-05-15 Årsstämma 2019
2019-04-25 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2018-11-09 Kvartalsrapport 2018-Q3
2018-08-10 Kvartalsrapport 2018-Q2
2018-05-16 Årsstämma 2018
2018-04-19 Kvartalsrapport 2018-Q1


ListaFirst North Stockholm
Iconovo är verksamt inom medicinteknik. Bolaget utvecklar inhalatorer för medicinskt bruk. Bolagets produkter används vid behandling utav astma och kol, där inhalatorerna består av pulverbaserat läkemedel. Produkterna licensieras ut och säljs under varierade varumärken. Utöver produktutveckling återfinns kompetens inom läkemedelsformulering. Bolaget grundades under 2013 och har sitt huvudkontor i Lund.
2024-05-15 13:50:00

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the company has filed a broad patent application related to inhaled GLP-1 receptor agonists. This marks the first step in Iconovo’s new initiative to develop more convenient, reliable, and cost-effective treatments for obesity. Based on its proprietary inhalers, the company aims to license out selected products after the preclinical proof-of-concept stage. Inhaled GLP-1 addresses a rapidly growing market, expected to reach USD 90 billion in 2029.

The inhaled GLP-1 products will be developed in Iconovo’s proprietary inhalers, primarily as a treatment for obesity with the opportunity to include other metabolic diseases like type 2 diabetes, fatty liver disease, cardiovascular disease and sleep apnea. The investments required in the initial development phase are limited.

“As a leading inhalation company, with a range of fully developed inhaler platforms and the competence to formulate pharmaceutical compounds into powders, we are in a perfect position to take a step into reformulation of selected high-value products in areas where inhalation can offer significant patient benefits. We are very excited to take this important step towards the development of a next generation of patient-friendly GLP-1 treatments with sustained efficacy”, says Johan Wäborg, CEO of Iconovo.

Most of today’s GLP-1 treatments, like Zepbound® (Eli Lilly) and Wegovy® (Novo Nordisk), are administered via subcutaneous injection, which is considered both stress- and painful by many patients. Iconovo’s inhaled treatments would give patients access to an alternative that is pain-free, and much more convenient. Since it is not an injection, there would be no requirements for cold storage to ensure the treatment’s durability, making inhaled treatment more reliable and cost-effective.

At present there is one oral GLP-1 treatment on the market, and more are under development. So far, bioavailability has been a major challenge with only about 1% of the active drug reaching its target. Iconovo estimates that inhaled GLP-1 would reach efficacy levels comparable to injected treatments, making it potentially competitively advantageous to oral treatments.

The patent application for inhaled GLP-1 receptor agonists addresses a very large and rapidly growing market presently worth USD 35 billion with an expectancy to grow at an annual rate of 17% to USD 90 billion in 2029. (Source: GlobalData).